Sistema de Salut de Catalunya
Institut Català de la Salut
[Bokemeyer C] The II Medical Clinic, Department of Oncology, Hematology & BMT with section of Pneumology, University Medical Center of Hamburg-Eppendorf, Hamburg, Germany. [Ciardiello F] Department of Precision Medicine, University of Campania Luigi Vanvitelli, Naples, Italy. [Dubreuil O] Medical Oncology Unit, Diaconesses-Croix St Simon Hospital, Paris, France. [Guigay J] Groupe d’Oncologie Radiothérapie Tête Et Cou (GORTEC), Tours, France. [Kasper S] Department of Medical Oncology, West German Cancer Center, University Hospital Essen, Essen, Germany. [Pfeiffer P] Department of Oncology, Odense University Hospital, Odense, Denmark. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2024-03-20T07:00:45Z
2024-03-20T07:00:45Z
2024-03
Dosing schedule; Efficacy; Pharmacokinetics
Programa de dosificació; Eficàcia; Farmacocinètica
Programa de dosificación; Eficacia; Farmacocinética
Cetuximab every 2 weeks (Q2W) dosing schedule is approved by the US FDA and by the Japanese Pharmaceuticals and Medical Devices Agency in patients with metastatic colorectal cancer and squamous cell carcinoma of the head and neck. Phase II trials have found comparable efficacy and safety for the weekly (Q1W) and Q2W schedules, and real-world studies have shown noninferiority of the Q2W compared with the Q1W schedule. Several guidelines recommend cetuximab Q2W administration as an alternative to the Q1W dosing schedule. Cetuximab Q2W can be administered with a Q2W dose of chemotherapy, making it a more convenient option to the Q1W schedule, potentially resulting in reduced costs for administration, increased flexibility for clinical staff and improved patient adherence.
Article
Published version
English
Càncer - Tractament; Anticossos monoclonals - Ús terapèutic; CHEMICALS AND DRUGS::Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Immunoproteins::Immunoglobulins::Antibodies::Antibodies, Monoclonal; Other subheadings::Other subheadings::/therapeutic use; DISEASES::Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; COMPUESTOS QUÍMICOS Y DROGAS::aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::inmunoproteínas::inmunoglobulinas::anticuerpos::anticuerpos monoclonales; Otros calificadores::Otros calificadores::/uso terapéutico; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
Future Medicine
Future Oncology;20(7)
https://doi.org/10.2217/fon-2023-0282
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
Articles científics - HVH [3439]
